education · health · HHS-NIH11
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
National Institutes of Health · PAR-25-070
Deadline
January 7, 2027
GRANTQUICK SUMMARYPlain-English Overview
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed). National Institutes of Health. The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists... Funding amounts not specified.
Who Should Apply
Nonprofits (non-501c3), County governments, Small businesses, Independent school districts, Other eligible entities (+10 more)
Who Should NOT Apply
Organizations not matching the eligible applicant types listed above
Key Requirements (Plain English)
- •Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Is...
- •Deadline: 2027-01-07
💡 GrantQuick Tip
Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.
Competitiveness: Moderate to high — federal grants are always competitive
What This Grant Funds
Attachments
Who Can Apply
Eligible Applicant Types
Funding Details
- Cost Sharing Required?
- No
- Funding Instrument
- grant
Key Dates
Agency Contact
NIH Grants Information grantsinfo@nih.gov
grantsinfo@nih.govReady to apply?
View the full NOFO and submit your application on Grants.gov